SCHEMBL4771251

SCHEMBL4771251

NC(C=O)N1CC=C(c2cc3ccccc3o2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
RAB9A P51151 5/20 0.36
NPC1 O15118 4/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
PRKDC P78527 1/20 0.36
ATM Q13315 1/20 0.36
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP2A6 P11509 1/20 0.35
POLB P06746 2/20 0.35
GRM4 Q14833 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10901794 0.74 NPC1 (0.46) MAPTRAB9ANPC1CHRM2CHRM4
SCHEMBL4906885 0.71 MAPT (0.58) MAPTRAB9ANPC1ALDH1A1HSD17B10
SCHEMBL8324685 0.69 DRD4 (0.61) MAPTKDM4EHTT
SCHEMBL15594939 0.69 PDK4 (0.53) MAPT
SCHEMBL4774596 0.68 MAPT (0.50) MAPT
SCHEMBL10901831 0.68 MAPT (0.53) MAPTRAB9ANPC1ALDH1A1KDM4E
SCHEMBL2085345 0.66 MAOB (0.45) MAPTRAB9ANPC1CHRM2CHRM4
SCHEMBL4148268 0.66 PRKDC (0.44) MAPTRAB9ANPC1CHRM2CHRM4
SCHEMBL29028841 0.65 TDP1 (0.46) MAPTRAB9ANPC1CHRM2CHRM4
SCHEMBL5585118 0.63 MAOB (0.47) MAPTRAB9ANPC1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed